BGI strategic realignment of the US subsidiary of a large-scale layoffs

Complete Genomics is a California-based gene sequencing company, in September 2012 was due to the $ 117 million BGI acquisition. According to the outgoing Complete Genomics CEO Cliff Reid (Cliff Reid), said Wang Jun resigned this summer after BGI CEO, the company began to reassess business strategies.
Today, BGI decided to become a subsidiary of Complete Genomics Genomics R & D center, the business center of gravity is no longer provided Revolocity gene sequencer. Complete Genomics June this year released Revolocity, the system is priced at $ 12 million, to be completed by 10,000 whole genome sequencing year.
So far, Revolocity won three customer orders, planned deliveries in the first half of next year. But Reid has said, now BGI after strategic adjustments, Complete Genomics is no longer accepted Revolocity orders. As for the previous three customers, we must delay delivery.
After the strategic adjustment, Complete Genomics will become a research and development center BGI to support products and clinical trials BGI. Complete Genomics has about 200 employees, Reid did not disclose how many employees will be affected.

( Bolise Co., Ltd. www.chemicalspharm.com )